Oppenheimer analyst Jay Olson raised the firm’s price target on Viking Therapeutics (VKTX) to $35 from $30 and keeps an Outperform rating on the shares ahead of the company’s Q1 update. The firm is encouraged by positive read-across from Madrigal Pharmaceuticals’ (MDGL) Phase 3 MAESTRO-NASH 52-week results, which reached statistical significance on both primary endpoints at 52-weeks.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics 17.242M share Spot Secondary priced at $14.50
- Viking Therapeutics Spot Secondary; price range $14.50-$15.00
- Viking Therapeutics announces common stock offering, no amount given
- Viking Therapeutics price target raised to $32 from $28 at Truist
